nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—kidney cancer—lung cancer	0.274	1	CtDrD
Pazopanib—FGFR1—lung cancer	0.0601	0.243	CbGaD
Pazopanib—FLT1—lung cancer	0.0575	0.232	CbGaD
Pazopanib—KDR—lung cancer	0.036	0.145	CbGaD
Pazopanib—KIT—lung cancer	0.034	0.137	CbGaD
Pazopanib—UGT1A1—lung cancer	0.0335	0.135	CbGaD
Pazopanib—LIMK2—Crizotinib—lung cancer	0.0223	0.0739	CbGbCtD
Pazopanib—PIP4K2C—Erlotinib—lung cancer	0.0216	0.0713	CbGbCtD
Pazopanib—ABCG2—lung cancer	0.0188	0.076	CbGaD
Pazopanib—BMPR1B—Crizotinib—lung cancer	0.0178	0.0587	CbGbCtD
Pazopanib—AURKC—Erlotinib—lung cancer	0.0171	0.0566	CbGbCtD
Pazopanib—STK10—Gefitinib—lung cancer	0.0166	0.055	CbGbCtD
Pazopanib—MAP2K5—Gefitinib—lung cancer	0.0151	0.0501	CbGbCtD
Pazopanib—TAOK3—Crizotinib—lung cancer	0.0149	0.0491	CbGbCtD
Pazopanib—PLK4—Crizotinib—lung cancer	0.0149	0.0491	CbGbCtD
Pazopanib—MAP3K19—Gefitinib—lung cancer	0.0139	0.046	CbGbCtD
Pazopanib—MAP3K2—Crizotinib—lung cancer	0.0128	0.0424	CbGbCtD
Pazopanib—EPHB6—Crizotinib—lung cancer	0.0113	0.0375	CbGbCtD
Pazopanib—LYN—Crizotinib—lung cancer	0.0113	0.0375	CbGbCtD
Pazopanib—STK10—Crizotinib—lung cancer	0.0102	0.0337	CbGbCtD
Pazopanib—CSF1R—Crizotinib—lung cancer	0.0102	0.0337	CbGbCtD
Pazopanib—STK10—Erlotinib—lung cancer	0.00984	0.0325	CbGbCtD
Pazopanib—LCK—Crizotinib—lung cancer	0.00928	0.0307	CbGbCtD
Pazopanib—MAP2K5—Erlotinib—lung cancer	0.00895	0.0296	CbGbCtD
Pazopanib—MAP3K19—Crizotinib—lung cancer	0.00853	0.0282	CbGbCtD
Pazopanib—MAP3K19—Erlotinib—lung cancer	0.00823	0.0272	CbGbCtD
Pazopanib—ABCB1—lung cancer	0.00784	0.0316	CbGaD
Pazopanib—ABCG2—Topotecan—lung cancer	0.003	0.00993	CbGbCtD
Pazopanib—UGT1A1—Erlotinib—lung cancer	0.00295	0.00976	CbGbCtD
Pazopanib—ABCG2—Gefitinib—lung cancer	0.00275	0.00908	CbGbCtD
Pazopanib—UGT1A1—Irinotecan—lung cancer	0.00267	0.00882	CbGbCtD
Pazopanib—ABCG2—Teniposide—lung cancer	0.00266	0.00881	CbGbCtD
Pazopanib—UGT1A1—Etoposide—lung cancer	0.00214	0.00706	CbGbCtD
Pazopanib—SLCO1B1—Irinotecan—lung cancer	0.00185	0.00611	CbGbCtD
Pazopanib—ABCG2—Erlotinib—lung cancer	0.00162	0.00537	CbGbCtD
Pazopanib—ABCG2—Paclitaxel—lung cancer	0.00149	0.00492	CbGbCtD
Pazopanib—ABCG2—Irinotecan—lung cancer	0.00147	0.00485	CbGbCtD
Pazopanib—ABCG2—Cisplatin—lung cancer	0.0012	0.00395	CbGbCtD
Pazopanib—ABCG2—Etoposide—lung cancer	0.00117	0.00388	CbGbCtD
Pazopanib—ABCB1—Topotecan—lung cancer	0.00108	0.00358	CbGbCtD
Pazopanib—ABCG2—Docetaxel—lung cancer	0.00107	0.00355	CbGbCtD
Pazopanib—ABCB1—Gefitinib—lung cancer	0.00099	0.00328	CbGbCtD
Pazopanib—SLCO1B1—Methotrexate—lung cancer	0.000977	0.00323	CbGbCtD
Pazopanib—CYP2D6—Gefitinib—lung cancer	0.000933	0.00309	CbGbCtD
Pazopanib—FLT1—umbilical vein—lung cancer	0.000893	0.0256	CbGeAlD
Pazopanib—CYP2C8—Erlotinib—lung cancer	0.000865	0.00286	CbGbCtD
Pazopanib—ABCG2—Doxorubicin—lung cancer	0.000801	0.00265	CbGbCtD
Pazopanib—CYP2C8—Paclitaxel—lung cancer	0.000792	0.00262	CbGbCtD
Pazopanib—ABCG2—Methotrexate—lung cancer	0.000776	0.00257	CbGbCtD
Pazopanib—ABCB1—Vinorelbine—lung cancer	0.000763	0.00252	CbGbCtD
Pazopanib—KDR—umbilical vein—lung cancer	0.000755	0.0216	CbGeAlD
Pazopanib—CYP2D6—Vinorelbine—lung cancer	0.000719	0.00238	CbGbCtD
Pazopanib—TAOK1—mammary gland—lung cancer	0.000713	0.0204	CbGeAlD
Pazopanib—SH2B3—mammary gland—lung cancer	0.000672	0.0192	CbGeAlD
Pazopanib—CYP1A2—Erlotinib—lung cancer	0.00067	0.00221	CbGbCtD
Pazopanib—CYP3A4—Topotecan—lung cancer	0.000649	0.00215	CbGbCtD
Pazopanib—Rilpivirine—ABCG2—lung cancer	0.000629	0.706	CrCbGaD
Pazopanib—CYP2C8—Etoposide—lung cancer	0.000626	0.00207	CbGbCtD
Pazopanib—ABCB1—Crizotinib—lung cancer	0.000607	0.00201	CbGbCtD
Pazopanib—CYP3A4—Gefitinib—lung cancer	0.000593	0.00196	CbGbCtD
Pazopanib—ABCB1—Gemcitabine—lung cancer	0.000593	0.00196	CbGbCtD
Pazopanib—ABCB1—Erlotinib—lung cancer	0.000586	0.00194	CbGbCtD
Pazopanib—CYP3A4—Teniposide—lung cancer	0.000575	0.0019	CbGbCtD
Pazopanib—CYP2D6—Erlotinib—lung cancer	0.000552	0.00182	CbGbCtD
Pazopanib—ABCB1—Paclitaxel—lung cancer	0.000536	0.00177	CbGbCtD
Pazopanib—MAP3K9—epithelium—lung cancer	0.000529	0.0152	CbGeAlD
Pazopanib—ABCB1—Irinotecan—lung cancer	0.000529	0.00175	CbGbCtD
Pazopanib—LIMK2—mammary gland—lung cancer	0.000488	0.014	CbGeAlD
Pazopanib—CYP1A2—Etoposide—lung cancer	0.000484	0.0016	CbGbCtD
Pazopanib—TAOK1—respiratory system—lung cancer	0.000475	0.0136	CbGeAlD
Pazopanib—ABCB1—Vinblastine—lung cancer	0.00047	0.00155	CbGbCtD
Pazopanib—CYP3A4—Vinorelbine—lung cancer	0.000457	0.00151	CbGbCtD
Pazopanib—CYP2D6—Vinblastine—lung cancer	0.000443	0.00147	CbGbCtD
Pazopanib—PIP4K2C—mammary gland—lung cancer	0.000436	0.0125	CbGeAlD
Pazopanib—ABCB1—Cisplatin—lung cancer	0.000431	0.00143	CbGbCtD
Pazopanib—ITK—bronchus—lung cancer	0.00043	0.0123	CbGeAlD
Pazopanib—ABCB1—Etoposide—lung cancer	0.000424	0.0014	CbGbCtD
Pazopanib—PLK4—respiratory system—lung cancer	0.000403	0.0115	CbGeAlD
Pazopanib—TAOK1—bronchus—lung cancer	0.000391	0.0112	CbGeAlD
Pazopanib—FGF1—mammary gland—lung cancer	0.00039	0.0112	CbGeAlD
Pazopanib—ABCB1—Docetaxel—lung cancer	0.000388	0.00128	CbGbCtD
Pazopanib—FGFR3—respiratory system—lung cancer	0.000375	0.0107	CbGeAlD
Pazopanib—MAP3K19—respiratory system—lung cancer	0.000371	0.0106	CbGeAlD
Pazopanib—PLK4—Topotecan—Irinotecan—lung cancer	0.000369	0.347	CbGdCrCtD
Pazopanib—SH2B3—bronchus—lung cancer	0.000368	0.0105	CbGeAlD
Pazopanib—FGFR2—mammary gland—lung cancer	0.000368	0.0105	CbGeAlD
Pazopanib—PLK4—Etoposide—Teniposide—lung cancer	0.000367	0.345	CbGdCrCtD
Pazopanib—CYP3A4—Crizotinib—lung cancer	0.000364	0.0012	CbGbCtD
Pazopanib—CYP3A4—Erlotinib—lung cancer	0.000351	0.00116	CbGbCtD
Pazopanib—MAP3K9—lung—lung cancer	0.000336	0.00963	CbGeAlD
Pazopanib—PI4KB—respiratory system—lung cancer	0.000331	0.00949	CbGeAlD
Pazopanib—SH2B3—trachea—lung cancer	0.000331	0.00947	CbGeAlD
Pazopanib—LIMK2—respiratory system—lung cancer	0.000325	0.00932	CbGeAlD
Pazopanib—CYP3A4—Paclitaxel—lung cancer	0.000321	0.00106	CbGbCtD
Pazopanib—PDGFRA—mammary gland—lung cancer	0.00032	0.00915	CbGeAlD
Pazopanib—CYP3A4—Irinotecan—lung cancer	0.000317	0.00105	CbGbCtD
Pazopanib—FGFR3—epithelium—lung cancer	0.000313	0.00897	CbGeAlD
Pazopanib—SH2B3—cardiac atrium—lung cancer	0.000311	0.0089	CbGeAlD
Pazopanib—BMPR1B—epithelium—lung cancer	0.00031	0.00888	CbGeAlD
Pazopanib—FGFR3—bronchus—lung cancer	0.000308	0.00883	CbGeAlD
Pazopanib—ITK—bone marrow—lung cancer	0.000306	0.00876	CbGeAlD
Pazopanib—BMPR1B—bronchus—lung cancer	0.000305	0.00874	CbGeAlD
Pazopanib—FLT4—respiratory system—lung cancer	0.000292	0.00837	CbGeAlD
Pazopanib—ABCB1—Doxorubicin—lung cancer	0.000289	0.000955	CbGbCtD
Pazopanib—KDR—mammary gland—lung cancer	0.000288	0.00826	CbGeAlD
Pazopanib—CYP3A4—Vinblastine—lung cancer	0.000282	0.000932	CbGbCtD
Pazopanib—CSF1R—mammary gland—lung cancer	0.000281	0.00806	CbGeAlD
Pazopanib—ABCB1—Methotrexate—lung cancer	0.00028	0.000925	CbGbCtD
Pazopanib—TAOK1—bone marrow—lung cancer	0.000279	0.00798	CbGeAlD
Pazopanib—ITK—lung—lung cancer	0.000277	0.00794	CbGeAlD
Pazopanib—STK36—bronchus—lung cancer	0.000277	0.00793	CbGeAlD
Pazopanib—PI4KB—bronchus—lung cancer	0.000273	0.00781	CbGeAlD
Pazopanib—CYP2D6—Doxorubicin—lung cancer	0.000272	0.0009	CbGbCtD
Pazopanib—LIMK2—bronchus—lung cancer	0.000268	0.00767	CbGeAlD
Pazopanib—SH2B3—bone marrow—lung cancer	0.000262	0.00751	CbGeAlD
Pazopanib—Rilpivirine—ABCB1—lung cancer	0.000262	0.294	CrCbGaD
Pazopanib—RIOK2—cardiac atrium—lung cancer	0.00026	0.00745	CbGeAlD
Pazopanib—FGF1—respiratory system—lung cancer	0.00026	0.00744	CbGeAlD
Pazopanib—KIT—mammary gland—lung cancer	0.000256	0.00732	CbGeAlD
Pazopanib—CYP3A4—Etoposide—lung cancer	0.000254	0.000839	CbGbCtD
Pazopanib—SLCO1B1—mammary gland—lung cancer	0.000254	0.00727	CbGeAlD
Pazopanib—TAOK1—lung—lung cancer	0.000252	0.00723	CbGeAlD
Pazopanib—PDGFRB—mammary gland—lung cancer	0.00025	0.00715	CbGeAlD
Pazopanib—STK36—trachea—lung cancer	0.000249	0.00712	CbGeAlD
Pazopanib—FGFR2—respiratory system—lung cancer	0.000245	0.00702	CbGeAlD
Pazopanib—PI4KB—trachea—lung cancer	0.000245	0.00701	CbGeAlD
Pazopanib—FLT4—epithelium—lung cancer	0.000244	0.007	CbGeAlD
Pazopanib—LIMK2—trachea—lung cancer	0.00024	0.00688	CbGeAlD
Pazopanib—PIP4K2C—bronchus—lung cancer	0.000239	0.00685	CbGeAlD
Pazopanib—SH2B3—lung—lung cancer	0.000238	0.00681	CbGeAlD
Pazopanib—FGFR1—bronchus—lung cancer	0.000237	0.0068	CbGeAlD
Pazopanib—PLK4—bone marrow—lung cancer	0.000236	0.00676	CbGeAlD
Pazopanib—CYP3A4—Docetaxel—lung cancer	0.000232	0.000768	CbGbCtD
Pazopanib—PI4KB—cardiac atrium—lung cancer	0.00023	0.00659	CbGeAlD
Pazopanib—MAP3K9—lymph node—lung cancer	0.00023	0.00659	CbGeAlD
Pazopanib—FLT1—respiratory system—lung cancer	0.000227	0.00651	CbGeAlD
Pazopanib—RIOK2—bone marrow—lung cancer	0.00022	0.00629	CbGeAlD
Pazopanib—FGF1—epithelium—lung cancer	0.000217	0.00621	CbGeAlD
Pazopanib—STK10—respiratory system—lung cancer	0.000215	0.00616	CbGeAlD
Pazopanib—PIP4K2C—trachea—lung cancer	0.000215	0.00615	CbGeAlD
Pazopanib—TAOK3—respiratory system—lung cancer	0.000214	0.00614	CbGeAlD
Pazopanib—PLK4—lung—lung cancer	0.000214	0.00613	CbGeAlD
Pazopanib—PDGFRA—respiratory system—lung cancer	0.000213	0.0061	CbGeAlD
Pazopanib—LCK—bronchus—lung cancer	0.000212	0.00608	CbGeAlD
Pazopanib—FGFR2—epithelium—lung cancer	0.000205	0.00587	CbGeAlD
Pazopanib—STK16—lung—lung cancer	0.000202	0.00579	CbGeAlD
Pazopanib—PIP4K2C—cardiac atrium—lung cancer	0.000202	0.00578	CbGeAlD
Pazopanib—FGFR1—cardiac atrium—lung cancer	0.0002	0.00573	CbGeAlD
Pazopanib—RIOK2—lung—lung cancer	0.000199	0.0057	CbGeAlD
Pazopanib—FGFR3—lung—lung cancer	0.000199	0.0057	CbGeAlD
Pazopanib—MAP3K19—lung—lung cancer	0.000197	0.00564	CbGeAlD
Pazopanib—BMPR1B—lung—lung cancer	0.000197	0.00564	CbGeAlD
Pazopanib—PI4KB—bone marrow—lung cancer	0.000194	0.00556	CbGeAlD
Pazopanib—KDR—respiratory system—lung cancer	0.000192	0.0055	CbGeAlD
Pazopanib—LCK—trachea—lung cancer	0.000191	0.00546	CbGeAlD
Pazopanib—FLT1—epithelium—lung cancer	0.00019	0.00544	CbGeAlD
Pazopanib—ITK—lymph node—lung cancer	0.00019	0.00543	CbGeAlD
Pazopanib—CSF1R—respiratory system—lung cancer	0.000188	0.00537	CbGeAlD
Pazopanib—FLT1—bronchus—lung cancer	0.000187	0.00536	CbGeAlD
Pazopanib—EPHB6—bronchus—lung cancer	0.000185	0.0053	CbGeAlD
Pazopanib—FGF1—cardiac atrium—lung cancer	0.00018	0.00516	CbGeAlD
Pazopanib—STK36—lung—lung cancer	0.000179	0.00512	CbGeAlD
Pazopanib—STK10—bronchus—lung cancer	0.000177	0.00507	CbGeAlD
Pazopanib—TAOK3—bronchus—lung cancer	0.000176	0.00505	CbGeAlD
Pazopanib—PI4KB—lung—lung cancer	0.000176	0.00504	CbGeAlD
Pazopanib—CYP3A4—Doxorubicin—lung cancer	0.000173	0.000572	CbGbCtD
Pazopanib—LIMK2—lung—lung cancer	0.000173	0.00495	CbGeAlD
Pazopanib—TAOK1—lymph node—lung cancer	0.000173	0.00494	CbGeAlD
Pazopanib—FLT4—bone marrow—lung cancer	0.000171	0.00491	CbGeAlD
Pazopanib—PIP4K2C—bone marrow—lung cancer	0.00017	0.00488	CbGeAlD
Pazopanib—KIT—respiratory system—lung cancer	0.00017	0.00488	CbGeAlD
Pazopanib—FLT1—trachea—lung cancer	0.000168	0.00481	CbGeAlD
Pazopanib—PLK4—Teniposide—Etoposide—lung cancer	0.000166	0.157	CbGdCrCtD
Pazopanib—PDGFRB—respiratory system—lung cancer	0.000166	0.00476	CbGeAlD
Pazopanib—EPHB6—trachea—lung cancer	0.000166	0.00475	CbGeAlD
Pazopanib—SH2B3—lymph node—lung cancer	0.000163	0.00465	CbGeAlD
Pazopanib—MAP3K2—bone marrow—lung cancer	0.000162	0.00463	CbGeAlD
Pazopanib—KDR—epithelium—lung cancer	0.000161	0.0046	CbGeAlD
Pazopanib—AURKC—lymph node—lung cancer	0.00016	0.00458	CbGeAlD
Pazopanib—TAOK3—trachea—lung cancer	0.000158	0.00454	CbGeAlD
Pazopanib—MAP2K5—bronchus—lung cancer	0.000158	0.00453	CbGeAlD
Pazopanib—KDR—bronchus—lung cancer	0.000158	0.00453	CbGeAlD
Pazopanib—FLT1—cardiac atrium—lung cancer	0.000158	0.00452	CbGeAlD
Pazopanib—PDGFRA—trachea—lung cancer	0.000157	0.00451	CbGeAlD
Pazopanib—EPHB6—cardiac atrium—lung cancer	0.000156	0.00447	CbGeAlD
Pazopanib—FLT4—lung—lung cancer	0.000155	0.00445	CbGeAlD
Pazopanib—PIP4K2C—lung—lung cancer	0.000154	0.00442	CbGeAlD
Pazopanib—CSF1R—bronchus—lung cancer	0.000154	0.00442	CbGeAlD
Pazopanib—FGFR1—lung—lung cancer	0.000153	0.00439	CbGeAlD
Pazopanib—LCK—bone marrow—lung cancer	0.000151	0.00433	CbGeAlD
Pazopanib—TAOK3—cardiac atrium—lung cancer	0.000149	0.00426	CbGeAlD
Pazopanib—MAP3K2—lung—lung cancer	0.000146	0.00419	CbGeAlD
Pazopanib—PLK4—lymph node—lung cancer	0.000146	0.00419	CbGeAlD
Pazopanib—CYP2C8—mammary gland—lung cancer	0.000144	0.00413	CbGeAlD
Pazopanib—KIT—epithelium—lung cancer	0.000142	0.00408	CbGeAlD
Pazopanib—MAP2K5—trachea—lung cancer	0.000142	0.00407	CbGeAlD
Pazopanib—KDR—trachea—lung cancer	0.000142	0.00407	CbGeAlD
Pazopanib—KIT—bronchus—lung cancer	0.00014	0.00401	CbGeAlD
Pazopanib—PDGFRB—epithelium—lung cancer	0.000139	0.00398	CbGeAlD
Pazopanib—CSF1R—trachea—lung cancer	0.000139	0.00397	CbGeAlD
Pazopanib—STK16—lymph node—lung cancer	0.000138	0.00396	CbGeAlD
Pazopanib—FGF1—lung—lung cancer	0.000138	0.00395	CbGeAlD
Pazopanib—LCK—lung—lung cancer	0.000137	0.00392	CbGeAlD
Pazopanib—PDGFRB—bronchus—lung cancer	0.000137	0.00392	CbGeAlD
Pazopanib—RIOK2—lymph node—lung cancer	0.000136	0.0039	CbGeAlD
Pazopanib—BMPR1B—lymph node—lung cancer	0.000135	0.00386	CbGeAlD
Pazopanib—KDR—cardiac atrium—lung cancer	0.000133	0.00382	CbGeAlD
Pazopanib—MAP2K5—cardiac atrium—lung cancer	0.000133	0.00382	CbGeAlD
Pazopanib—FGFR2—lung—lung cancer	0.00013	0.00373	CbGeAlD
Pazopanib—CSF1R—cardiac atrium—lung cancer	0.00013	0.00373	CbGeAlD
Pazopanib—STK10—bone marrow—lung cancer	0.000126	0.00361	CbGeAlD
Pazopanib—KIT—trachea—lung cancer	0.000126	0.0036	CbGeAlD
Pazopanib—TAOK3—bone marrow—lung cancer	0.000126	0.0036	CbGeAlD
Pazopanib—PDGFRB—trachea—lung cancer	0.000123	0.00352	CbGeAlD
Pazopanib—STK36—lymph node—lung cancer	0.000122	0.0035	CbGeAlD
Pazopanib—FLT1—lung—lung cancer	0.000121	0.00346	CbGeAlD
Pazopanib—PI4KB—lymph node—lung cancer	0.00012	0.00345	CbGeAlD
Pazopanib—EPHB6—lung—lung cancer	0.000119	0.00342	CbGeAlD
Pazopanib—LIMK2—lymph node—lung cancer	0.000118	0.00338	CbGeAlD
Pazopanib—PDGFRB—cardiac atrium—lung cancer	0.000115	0.00331	CbGeAlD
Pazopanib—STK10—lung—lung cancer	0.000114	0.00327	CbGeAlD
Pazopanib—TAOK3—lung—lung cancer	0.000114	0.00326	CbGeAlD
Pazopanib—PDGFRA—lung—lung cancer	0.000113	0.00324	CbGeAlD
Pazopanib—KDR—bone marrow—lung cancer	0.000113	0.00322	CbGeAlD
Pazopanib—CSF1R—bone marrow—lung cancer	0.00011	0.00315	CbGeAlD
Pazopanib—FLT4—lymph node—lung cancer	0.000106	0.00304	CbGeAlD
Pazopanib—PIP4K2C—lymph node—lung cancer	0.000106	0.00302	CbGeAlD
Pazopanib—FGFR1—lymph node—lung cancer	0.000105	0.003	CbGeAlD
Pazopanib—KDR—lung—lung cancer	0.000102	0.00292	CbGeAlD
Pazopanib—MAP2K5—lung—lung cancer	0.000102	0.00292	CbGeAlD
Pazopanib—MAP3K2—lymph node—lung cancer	0.0001	0.00287	CbGeAlD
Pazopanib—KIT—bone marrow—lung cancer	9.98e-05	0.00286	CbGeAlD
Pazopanib—CSF1R—lung—lung cancer	9.96e-05	0.00285	CbGeAlD
Pazopanib—PDGFRB—bone marrow—lung cancer	9.75e-05	0.00279	CbGeAlD
Pazopanib—FGF1—lymph node—lung cancer	9.43e-05	0.0027	CbGeAlD
Pazopanib—LCK—lymph node—lung cancer	9.37e-05	0.00268	CbGeAlD
Pazopanib—KIT—lung—lung cancer	9.04e-05	0.00259	CbGeAlD
Pazopanib—CYP1A2—respiratory system—lung cancer	9e-05	0.00258	CbGeAlD
Pazopanib—PDGFRB—lung—lung cancer	8.83e-05	0.00253	CbGeAlD
Pazopanib—FLT1—lymph node—lung cancer	8.25e-05	0.00236	CbGeAlD
Pazopanib—EPHB6—lymph node—lung cancer	8.16e-05	0.00234	CbGeAlD
Pazopanib—PLK4—Epirubicin—Doxorubicin—lung cancer	8.03e-05	0.0755	CbGdCrCtD
Pazopanib—PLK4—Idarubicin—Doxorubicin—lung cancer	8.03e-05	0.0755	CbGdCrCtD
Pazopanib—STK10—lymph node—lung cancer	7.81e-05	0.00224	CbGeAlD
Pazopanib—TAOK3—lymph node—lung cancer	7.78e-05	0.00223	CbGeAlD
Pazopanib—PDGFRA—lymph node—lung cancer	7.74e-05	0.00222	CbGeAlD
Pazopanib—KDR—lymph node—lung cancer	6.98e-05	0.002	CbGeAlD
Pazopanib—MAP2K5—lymph node—lung cancer	6.98e-05	0.002	CbGeAlD
Pazopanib—CSF1R—lymph node—lung cancer	6.81e-05	0.00195	CbGeAlD
Pazopanib—KIT—lymph node—lung cancer	6.18e-05	0.00177	CbGeAlD
Pazopanib—PDGFRB—lymph node—lung cancer	6.04e-05	0.00173	CbGeAlD
Pazopanib—ABCG2—bone marrow—lung cancer	5.48e-05	0.00157	CbGeAlD
Pazopanib—ABCG2—lung—lung cancer	4.96e-05	0.00142	CbGeAlD
Pazopanib—CYP1A2—lung—lung cancer	4.78e-05	0.00137	CbGeAlD
Pazopanib—ABCB1—respiratory system—lung cancer	4.61e-05	0.00132	CbGeAlD
Pazopanib—ABCB1—epithelium—lung cancer	3.85e-05	0.0011	CbGeAlD
Pazopanib—ABCB1—trachea—lung cancer	3.41e-05	0.000975	CbGeAlD
Pazopanib—ABCG2—lymph node—lung cancer	3.39e-05	0.000972	CbGeAlD
Pazopanib—ABCB1—bone marrow—lung cancer	2.7e-05	0.000774	CbGeAlD
Pazopanib—ABCB1—lung—lung cancer	2.45e-05	0.000701	CbGeAlD
Pazopanib—Abdominal pain upper—Doxorubicin—lung cancer	1.89e-05	0.000278	CcSEcCtD
Pazopanib—Nervous system disorder—Paclitaxel—lung cancer	1.89e-05	0.000278	CcSEcCtD
Pazopanib—Photosensitivity reaction—Methotrexate—lung cancer	1.89e-05	0.000278	CcSEcCtD
Pazopanib—Thrombocytopenia—Paclitaxel—lung cancer	1.88e-05	0.000277	CcSEcCtD
Pazopanib—Breast disorder—Doxorubicin—lung cancer	1.87e-05	0.000275	CcSEcCtD
Pazopanib—Anorexia—Etoposide—lung cancer	1.87e-05	0.000275	CcSEcCtD
Pazopanib—Skin disorder—Paclitaxel—lung cancer	1.87e-05	0.000275	CcSEcCtD
Pazopanib—Abdominal pain—Irinotecan—lung cancer	1.87e-05	0.000274	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Doxorubicin—lung cancer	1.87e-05	0.000274	CcSEcCtD
Pazopanib—Decreased appetite—Cisplatin—lung cancer	1.86e-05	0.000274	CcSEcCtD
Pazopanib—Hyperhidrosis—Paclitaxel—lung cancer	1.86e-05	0.000274	CcSEcCtD
Pazopanib—Nasopharyngitis—Doxorubicin—lung cancer	1.85e-05	0.000272	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Cisplatin—lung cancer	1.85e-05	0.000272	CcSEcCtD
Pazopanib—Anaemia—Docetaxel—lung cancer	1.85e-05	0.000272	CcSEcCtD
Pazopanib—Infestation NOS—Methotrexate—lung cancer	1.84e-05	0.000271	CcSEcCtD
Pazopanib—Infestation—Methotrexate—lung cancer	1.84e-05	0.000271	CcSEcCtD
Pazopanib—Anorexia—Paclitaxel—lung cancer	1.83e-05	0.00027	CcSEcCtD
Pazopanib—Pain—Cisplatin—lung cancer	1.83e-05	0.000269	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Doxorubicin—lung cancer	1.83e-05	0.000269	CcSEcCtD
Pazopanib—Vomiting—Vinorelbine—lung cancer	1.82e-05	0.000268	CcSEcCtD
Pazopanib—Rash—Vinorelbine—lung cancer	1.8e-05	0.000265	CcSEcCtD
Pazopanib—Dermatitis—Vinorelbine—lung cancer	1.8e-05	0.000265	CcSEcCtD
Pazopanib—Abdominal distension—Doxorubicin—lung cancer	1.8e-05	0.000265	CcSEcCtD
Pazopanib—Stomatitis—Methotrexate—lung cancer	1.8e-05	0.000264	CcSEcCtD
Pazopanib—Headache—Vinorelbine—lung cancer	1.79e-05	0.000264	CcSEcCtD
Pazopanib—Syncope—Docetaxel—lung cancer	1.79e-05	0.000264	CcSEcCtD
Pazopanib—Leukopenia—Docetaxel—lung cancer	1.79e-05	0.000263	CcSEcCtD
Pazopanib—Paraesthesia—Etoposide—lung cancer	1.76e-05	0.000259	CcSEcCtD
Pazopanib—Haematuria—Methotrexate—lung cancer	1.76e-05	0.000259	CcSEcCtD
Pazopanib—Loss of consciousness—Docetaxel—lung cancer	1.76e-05	0.000258	CcSEcCtD
Pazopanib—Pancreatitis—Doxorubicin—lung cancer	1.76e-05	0.000258	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Paclitaxel—lung cancer	1.75e-05	0.000258	CcSEcCtD
Pazopanib—Dyspnoea—Etoposide—lung cancer	1.75e-05	0.000257	CcSEcCtD
Pazopanib—Somnolence—Etoposide—lung cancer	1.74e-05	0.000257	CcSEcCtD
Pazopanib—Cough—Docetaxel—lung cancer	1.74e-05	0.000257	CcSEcCtD
Pazopanib—Hepatobiliary disease—Methotrexate—lung cancer	1.74e-05	0.000256	CcSEcCtD
Pazopanib—Insomnia—Paclitaxel—lung cancer	1.74e-05	0.000256	CcSEcCtD
Pazopanib—Epistaxis—Methotrexate—lung cancer	1.74e-05	0.000256	CcSEcCtD
Pazopanib—Paraesthesia—Paclitaxel—lung cancer	1.73e-05	0.000254	CcSEcCtD
Pazopanib—Hypertension—Docetaxel—lung cancer	1.73e-05	0.000254	CcSEcCtD
Pazopanib—Dyspnoea—Paclitaxel—lung cancer	1.72e-05	0.000252	CcSEcCtD
Pazopanib—Somnolence—Paclitaxel—lung cancer	1.71e-05	0.000252	CcSEcCtD
Pazopanib—Decreased appetite—Etoposide—lung cancer	1.71e-05	0.000251	CcSEcCtD
Pazopanib—Arthralgia—Docetaxel—lung cancer	1.7e-05	0.00025	CcSEcCtD
Pazopanib—Myalgia—Docetaxel—lung cancer	1.7e-05	0.00025	CcSEcCtD
Pazopanib—Chest pain—Docetaxel—lung cancer	1.7e-05	0.00025	CcSEcCtD
Pazopanib—Nausea—Vinorelbine—lung cancer	1.7e-05	0.00025	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Etoposide—lung cancer	1.69e-05	0.000249	CcSEcCtD
Pazopanib—Dyspepsia—Paclitaxel—lung cancer	1.69e-05	0.000249	CcSEcCtD
Pazopanib—Asthenia—Irinotecan—lung cancer	1.69e-05	0.000249	CcSEcCtD
Pazopanib—Fatigue—Etoposide—lung cancer	1.69e-05	0.000249	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	1.69e-05	0.000249	CcSEcCtD
Pazopanib—Pain—Etoposide—lung cancer	1.68e-05	0.000247	CcSEcCtD
Pazopanib—ABCB1—lymph node—lung cancer	1.67e-05	0.000479	CbGeAlD
Pazopanib—Neutropenia—Doxorubicin—lung cancer	1.67e-05	0.000246	CcSEcCtD
Pazopanib—Decreased appetite—Paclitaxel—lung cancer	1.67e-05	0.000246	CcSEcCtD
Pazopanib—Dry mouth—Docetaxel—lung cancer	1.66e-05	0.000245	CcSEcCtD
Pazopanib—Haemoglobin—Methotrexate—lung cancer	1.66e-05	0.000245	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Paclitaxel—lung cancer	1.66e-05	0.000244	CcSEcCtD
Pazopanib—Fatigue—Paclitaxel—lung cancer	1.66e-05	0.000244	CcSEcCtD
Pazopanib—Haemorrhage—Methotrexate—lung cancer	1.65e-05	0.000243	CcSEcCtD
Pazopanib—Asthenia—Gemcitabine—lung cancer	1.65e-05	0.000243	CcSEcCtD
Pazopanib—Pain—Paclitaxel—lung cancer	1.65e-05	0.000242	CcSEcCtD
Pazopanib—Urinary tract disorder—Methotrexate—lung cancer	1.63e-05	0.00024	CcSEcCtD
Pazopanib—Photosensitivity reaction—Doxorubicin—lung cancer	1.63e-05	0.00024	CcSEcCtD
Pazopanib—Oedema—Docetaxel—lung cancer	1.63e-05	0.00024	CcSEcCtD
Pazopanib—Pruritus—Gemcitabine—lung cancer	1.63e-05	0.000239	CcSEcCtD
Pazopanib—Urethral disorder—Methotrexate—lung cancer	1.62e-05	0.000239	CcSEcCtD
Pazopanib—Infection—Docetaxel—lung cancer	1.62e-05	0.000238	CcSEcCtD
Pazopanib—Weight decreased—Doxorubicin—lung cancer	1.62e-05	0.000238	CcSEcCtD
Pazopanib—Diarrhoea—Irinotecan—lung cancer	1.61e-05	0.000237	CcSEcCtD
Pazopanib—Gastrointestinal pain—Etoposide—lung cancer	1.6e-05	0.000236	CcSEcCtD
Pazopanib—Shock—Docetaxel—lung cancer	1.6e-05	0.000236	CcSEcCtD
Pazopanib—Nervous system disorder—Docetaxel—lung cancer	1.6e-05	0.000235	CcSEcCtD
Pazopanib—Thrombocytopenia—Docetaxel—lung cancer	1.6e-05	0.000235	CcSEcCtD
Pazopanib—Infestation NOS—Doxorubicin—lung cancer	1.6e-05	0.000235	CcSEcCtD
Pazopanib—Infestation—Doxorubicin—lung cancer	1.6e-05	0.000235	CcSEcCtD
Pazopanib—Skin disorder—Docetaxel—lung cancer	1.58e-05	0.000233	CcSEcCtD
Pazopanib—Gastrointestinal pain—Paclitaxel—lung cancer	1.57e-05	0.000231	CcSEcCtD
Pazopanib—Diarrhoea—Gemcitabine—lung cancer	1.57e-05	0.000231	CcSEcCtD
Pazopanib—Dizziness—Irinotecan—lung cancer	1.56e-05	0.00023	CcSEcCtD
Pazopanib—Stomatitis—Doxorubicin—lung cancer	1.56e-05	0.000229	CcSEcCtD
Pazopanib—Jaundice—Doxorubicin—lung cancer	1.56e-05	0.000229	CcSEcCtD
Pazopanib—Anorexia—Docetaxel—lung cancer	1.55e-05	0.000229	CcSEcCtD
Pazopanib—Abdominal pain—Etoposide—lung cancer	1.55e-05	0.000228	CcSEcCtD
Pazopanib—Eye disorder—Methotrexate—lung cancer	1.55e-05	0.000227	CcSEcCtD
Pazopanib—Asthenia—Cisplatin—lung cancer	1.54e-05	0.000226	CcSEcCtD
Pazopanib—Cardiac disorder—Methotrexate—lung cancer	1.54e-05	0.000226	CcSEcCtD
Pazopanib—Haematuria—Doxorubicin—lung cancer	1.52e-05	0.000224	CcSEcCtD
Pazopanib—Abdominal pain—Paclitaxel—lung cancer	1.52e-05	0.000224	CcSEcCtD
Pazopanib—Hepatobiliary disease—Doxorubicin—lung cancer	1.51e-05	0.000222	CcSEcCtD
Pazopanib—Epistaxis—Doxorubicin—lung cancer	1.51e-05	0.000221	CcSEcCtD
Pazopanib—Angiopathy—Methotrexate—lung cancer	1.5e-05	0.000221	CcSEcCtD
Pazopanib—Vomiting—Irinotecan—lung cancer	1.5e-05	0.000221	CcSEcCtD
Pazopanib—Mediastinal disorder—Methotrexate—lung cancer	1.49e-05	0.000219	CcSEcCtD
Pazopanib—Rash—Irinotecan—lung cancer	1.49e-05	0.000219	CcSEcCtD
Pazopanib—Dermatitis—Irinotecan—lung cancer	1.49e-05	0.000219	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Docetaxel—lung cancer	1.49e-05	0.000219	CcSEcCtD
Pazopanib—Chills—Methotrexate—lung cancer	1.48e-05	0.000218	CcSEcCtD
Pazopanib—Headache—Irinotecan—lung cancer	1.48e-05	0.000217	CcSEcCtD
Pazopanib—Insomnia—Docetaxel—lung cancer	1.48e-05	0.000217	CcSEcCtD
Pazopanib—Diarrhoea—Cisplatin—lung cancer	1.47e-05	0.000216	CcSEcCtD
Pazopanib—Paraesthesia—Docetaxel—lung cancer	1.46e-05	0.000215	CcSEcCtD
Pazopanib—Alopecia—Methotrexate—lung cancer	1.46e-05	0.000215	CcSEcCtD
Pazopanib—Vomiting—Gemcitabine—lung cancer	1.46e-05	0.000215	CcSEcCtD
Pazopanib—Bradycardia—Doxorubicin—lung cancer	1.46e-05	0.000215	CcSEcCtD
Pazopanib—Dyspnoea—Docetaxel—lung cancer	1.45e-05	0.000214	CcSEcCtD
Pazopanib—Somnolence—Docetaxel—lung cancer	1.45e-05	0.000213	CcSEcCtD
Pazopanib—Mental disorder—Methotrexate—lung cancer	1.45e-05	0.000213	CcSEcCtD
Pazopanib—Rash—Gemcitabine—lung cancer	1.45e-05	0.000213	CcSEcCtD
Pazopanib—Dermatitis—Gemcitabine—lung cancer	1.45e-05	0.000213	CcSEcCtD
Pazopanib—Erythema—Methotrexate—lung cancer	1.44e-05	0.000212	CcSEcCtD
Pazopanib—Malnutrition—Methotrexate—lung cancer	1.44e-05	0.000212	CcSEcCtD
Pazopanib—Haemoglobin—Doxorubicin—lung cancer	1.44e-05	0.000212	CcSEcCtD
Pazopanib—Headache—Gemcitabine—lung cancer	1.44e-05	0.000212	CcSEcCtD
Pazopanib—Dyspepsia—Docetaxel—lung cancer	1.44e-05	0.000211	CcSEcCtD
Pazopanib—Haemorrhage—Doxorubicin—lung cancer	1.43e-05	0.000211	CcSEcCtD
Pazopanib—Hypoaesthesia—Doxorubicin—lung cancer	1.43e-05	0.00021	CcSEcCtD
Pazopanib—Decreased appetite—Docetaxel—lung cancer	1.42e-05	0.000209	CcSEcCtD
Pazopanib—Urinary tract disorder—Doxorubicin—lung cancer	1.41e-05	0.000208	CcSEcCtD
Pazopanib—Oedema peripheral—Doxorubicin—lung cancer	1.41e-05	0.000208	CcSEcCtD
Pazopanib—Dysgeusia—Methotrexate—lung cancer	1.41e-05	0.000207	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Docetaxel—lung cancer	1.41e-05	0.000207	CcSEcCtD
Pazopanib—Asthenia—Etoposide—lung cancer	1.41e-05	0.000207	CcSEcCtD
Pazopanib—Connective tissue disorder—Doxorubicin—lung cancer	1.41e-05	0.000207	CcSEcCtD
Pazopanib—Fatigue—Docetaxel—lung cancer	1.41e-05	0.000207	CcSEcCtD
Pazopanib—Urethral disorder—Doxorubicin—lung cancer	1.4e-05	0.000207	CcSEcCtD
Pazopanib—Nausea—Irinotecan—lung cancer	1.4e-05	0.000206	CcSEcCtD
Pazopanib—Pain—Docetaxel—lung cancer	1.39e-05	0.000205	CcSEcCtD
Pazopanib—Pruritus—Etoposide—lung cancer	1.39e-05	0.000204	CcSEcCtD
Pazopanib—Asthenia—Paclitaxel—lung cancer	1.38e-05	0.000203	CcSEcCtD
Pazopanib—Nausea—Gemcitabine—lung cancer	1.37e-05	0.000201	CcSEcCtD
Pazopanib—Vomiting—Cisplatin—lung cancer	1.36e-05	0.0002	CcSEcCtD
Pazopanib—Pruritus—Paclitaxel—lung cancer	1.36e-05	0.0002	CcSEcCtD
Pazopanib—Vision blurred—Methotrexate—lung cancer	1.36e-05	0.0002	CcSEcCtD
Pazopanib—Rash—Cisplatin—lung cancer	1.35e-05	0.000199	CcSEcCtD
Pazopanib—Dermatitis—Cisplatin—lung cancer	1.35e-05	0.000198	CcSEcCtD
Pazopanib—Diarrhoea—Etoposide—lung cancer	1.34e-05	0.000198	CcSEcCtD
Pazopanib—Eye disorder—Doxorubicin—lung cancer	1.34e-05	0.000197	CcSEcCtD
Pazopanib—Gastrointestinal pain—Docetaxel—lung cancer	1.33e-05	0.000196	CcSEcCtD
Pazopanib—Anaemia—Methotrexate—lung cancer	1.33e-05	0.000196	CcSEcCtD
Pazopanib—Flushing—Doxorubicin—lung cancer	1.33e-05	0.000196	CcSEcCtD
Pazopanib—Cardiac disorder—Doxorubicin—lung cancer	1.33e-05	0.000196	CcSEcCtD
Pazopanib—Diarrhoea—Paclitaxel—lung cancer	1.32e-05	0.000194	CcSEcCtD
Pazopanib—Angiopathy—Doxorubicin—lung cancer	1.3e-05	0.000191	CcSEcCtD
Pazopanib—Dizziness—Etoposide—lung cancer	1.3e-05	0.000191	CcSEcCtD
Pazopanib—Mediastinal disorder—Doxorubicin—lung cancer	1.29e-05	0.00019	CcSEcCtD
Pazopanib—Abdominal pain—Docetaxel—lung cancer	1.29e-05	0.00019	CcSEcCtD
Pazopanib—Leukopenia—Methotrexate—lung cancer	1.29e-05	0.00019	CcSEcCtD
Pazopanib—Chills—Doxorubicin—lung cancer	1.29e-05	0.000189	CcSEcCtD
Pazopanib—Dizziness—Paclitaxel—lung cancer	1.27e-05	0.000187	CcSEcCtD
Pazopanib—Nausea—Cisplatin—lung cancer	1.27e-05	0.000187	CcSEcCtD
Pazopanib—Alopecia—Doxorubicin—lung cancer	1.27e-05	0.000186	CcSEcCtD
Pazopanib—Cough—Methotrexate—lung cancer	1.26e-05	0.000185	CcSEcCtD
Pazopanib—Mental disorder—Doxorubicin—lung cancer	1.26e-05	0.000185	CcSEcCtD
Pazopanib—Vomiting—Etoposide—lung cancer	1.25e-05	0.000184	CcSEcCtD
Pazopanib—Erythema—Doxorubicin—lung cancer	1.25e-05	0.000183	CcSEcCtD
Pazopanib—Malnutrition—Doxorubicin—lung cancer	1.25e-05	0.000183	CcSEcCtD
Pazopanib—Rash—Etoposide—lung cancer	1.24e-05	0.000182	CcSEcCtD
Pazopanib—Dermatitis—Etoposide—lung cancer	1.24e-05	0.000182	CcSEcCtD
Pazopanib—Headache—Etoposide—lung cancer	1.23e-05	0.000181	CcSEcCtD
Pazopanib—Flatulence—Doxorubicin—lung cancer	1.23e-05	0.000181	CcSEcCtD
Pazopanib—Myalgia—Methotrexate—lung cancer	1.23e-05	0.00018	CcSEcCtD
Pazopanib—Chest pain—Methotrexate—lung cancer	1.23e-05	0.00018	CcSEcCtD
Pazopanib—Arthralgia—Methotrexate—lung cancer	1.23e-05	0.00018	CcSEcCtD
Pazopanib—Vomiting—Paclitaxel—lung cancer	1.22e-05	0.00018	CcSEcCtD
Pazopanib—Dysgeusia—Doxorubicin—lung cancer	1.22e-05	0.00018	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	1.22e-05	0.000179	CcSEcCtD
Pazopanib—Rash—Paclitaxel—lung cancer	1.21e-05	0.000178	CcSEcCtD
Pazopanib—Dermatitis—Paclitaxel—lung cancer	1.21e-05	0.000178	CcSEcCtD
Pazopanib—Headache—Paclitaxel—lung cancer	1.21e-05	0.000177	CcSEcCtD
Pazopanib—Muscle spasms—Doxorubicin—lung cancer	1.2e-05	0.000176	CcSEcCtD
Pazopanib—Vision blurred—Doxorubicin—lung cancer	1.18e-05	0.000173	CcSEcCtD
Pazopanib—Asthenia—Docetaxel—lung cancer	1.17e-05	0.000172	CcSEcCtD
Pazopanib—Infection—Methotrexate—lung cancer	1.17e-05	0.000172	CcSEcCtD
Pazopanib—Nausea—Etoposide—lung cancer	1.17e-05	0.000171	CcSEcCtD
Pazopanib—Pruritus—Docetaxel—lung cancer	1.15e-05	0.00017	CcSEcCtD
Pazopanib—Nervous system disorder—Methotrexate—lung cancer	1.15e-05	0.00017	CcSEcCtD
Pazopanib—Anaemia—Doxorubicin—lung cancer	1.15e-05	0.00017	CcSEcCtD
Pazopanib—Thrombocytopenia—Methotrexate—lung cancer	1.15e-05	0.000169	CcSEcCtD
Pazopanib—Nausea—Paclitaxel—lung cancer	1.14e-05	0.000168	CcSEcCtD
Pazopanib—Skin disorder—Methotrexate—lung cancer	1.14e-05	0.000168	CcSEcCtD
Pazopanib—Hyperhidrosis—Methotrexate—lung cancer	1.14e-05	0.000167	CcSEcCtD
Pazopanib—Anorexia—Methotrexate—lung cancer	1.12e-05	0.000165	CcSEcCtD
Pazopanib—Syncope—Doxorubicin—lung cancer	1.12e-05	0.000165	CcSEcCtD
Pazopanib—Leukopenia—Doxorubicin—lung cancer	1.12e-05	0.000164	CcSEcCtD
Pazopanib—Diarrhoea—Docetaxel—lung cancer	1.12e-05	0.000164	CcSEcCtD
Pazopanib—Loss of consciousness—Doxorubicin—lung cancer	1.1e-05	0.000161	CcSEcCtD
Pazopanib—Cough—Doxorubicin—lung cancer	1.09e-05	0.00016	CcSEcCtD
Pazopanib—Dizziness—Docetaxel—lung cancer	1.08e-05	0.000159	CcSEcCtD
Pazopanib—Hypertension—Doxorubicin—lung cancer	1.08e-05	0.000158	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Methotrexate—lung cancer	1.07e-05	0.000158	CcSEcCtD
Pazopanib—Insomnia—Methotrexate—lung cancer	1.06e-05	0.000156	CcSEcCtD
Pazopanib—Arthralgia—Doxorubicin—lung cancer	1.06e-05	0.000156	CcSEcCtD
Pazopanib—Myalgia—Doxorubicin—lung cancer	1.06e-05	0.000156	CcSEcCtD
Pazopanib—Chest pain—Doxorubicin—lung cancer	1.06e-05	0.000156	CcSEcCtD
Pazopanib—Paraesthesia—Methotrexate—lung cancer	1.06e-05	0.000155	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	1.05e-05	0.000155	CcSEcCtD
Pazopanib—Dyspnoea—Methotrexate—lung cancer	1.05e-05	0.000154	CcSEcCtD
Pazopanib—Somnolence—Methotrexate—lung cancer	1.05e-05	0.000154	CcSEcCtD
Pazopanib—Dry mouth—Doxorubicin—lung cancer	1.04e-05	0.000153	CcSEcCtD
Pazopanib—Vomiting—Docetaxel—lung cancer	1.04e-05	0.000153	CcSEcCtD
Pazopanib—Dyspepsia—Methotrexate—lung cancer	1.03e-05	0.000152	CcSEcCtD
Pazopanib—Rash—Docetaxel—lung cancer	1.03e-05	0.000151	CcSEcCtD
Pazopanib—Dermatitis—Docetaxel—lung cancer	1.03e-05	0.000151	CcSEcCtD
Pazopanib—Decreased appetite—Methotrexate—lung cancer	1.02e-05	0.00015	CcSEcCtD
Pazopanib—Headache—Docetaxel—lung cancer	1.02e-05	0.00015	CcSEcCtD
Pazopanib—Oedema—Doxorubicin—lung cancer	1.02e-05	0.00015	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Methotrexate—lung cancer	1.01e-05	0.000149	CcSEcCtD
Pazopanib—Fatigue—Methotrexate—lung cancer	1.01e-05	0.000149	CcSEcCtD
Pazopanib—Infection—Doxorubicin—lung cancer	1.01e-05	0.000149	CcSEcCtD
Pazopanib—Pain—Methotrexate—lung cancer	1.01e-05	0.000148	CcSEcCtD
Pazopanib—Shock—Doxorubicin—lung cancer	1e-05	0.000147	CcSEcCtD
Pazopanib—Nervous system disorder—Doxorubicin—lung cancer	9.98e-06	0.000147	CcSEcCtD
Pazopanib—Thrombocytopenia—Doxorubicin—lung cancer	9.97e-06	0.000147	CcSEcCtD
Pazopanib—Skin disorder—Doxorubicin—lung cancer	9.89e-06	0.000145	CcSEcCtD
Pazopanib—Hyperhidrosis—Doxorubicin—lung cancer	9.84e-06	0.000145	CcSEcCtD
Pazopanib—Anorexia—Doxorubicin—lung cancer	9.7e-06	0.000143	CcSEcCtD
Pazopanib—Nausea—Docetaxel—lung cancer	9.69e-06	0.000143	CcSEcCtD
Pazopanib—Gastrointestinal pain—Methotrexate—lung cancer	9.61e-06	0.000141	CcSEcCtD
Pazopanib—Abdominal pain—Methotrexate—lung cancer	9.29e-06	0.000137	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Doxorubicin—lung cancer	9.27e-06	0.000136	CcSEcCtD
Pazopanib—Insomnia—Doxorubicin—lung cancer	9.21e-06	0.000135	CcSEcCtD
Pazopanib—Paraesthesia—Doxorubicin—lung cancer	9.14e-06	0.000134	CcSEcCtD
Pazopanib—Dyspnoea—Doxorubicin—lung cancer	9.08e-06	0.000133	CcSEcCtD
Pazopanib—Somnolence—Doxorubicin—lung cancer	9.05e-06	0.000133	CcSEcCtD
Pazopanib—Dyspepsia—Doxorubicin—lung cancer	8.96e-06	0.000132	CcSEcCtD
Pazopanib—Decreased appetite—Doxorubicin—lung cancer	8.85e-06	0.00013	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Doxorubicin—lung cancer	8.79e-06	0.000129	CcSEcCtD
Pazopanib—Fatigue—Doxorubicin—lung cancer	8.78e-06	0.000129	CcSEcCtD
Pazopanib—Pain—Doxorubicin—lung cancer	8.71e-06	0.000128	CcSEcCtD
Pazopanib—Asthenia—Methotrexate—lung cancer	8.43e-06	0.000124	CcSEcCtD
Pazopanib—Gastrointestinal pain—Doxorubicin—lung cancer	8.32e-06	0.000122	CcSEcCtD
Pazopanib—Pruritus—Methotrexate—lung cancer	8.32e-06	0.000122	CcSEcCtD
Pazopanib—Abdominal pain—Doxorubicin—lung cancer	8.05e-06	0.000118	CcSEcCtD
Pazopanib—Diarrhoea—Methotrexate—lung cancer	8.04e-06	0.000118	CcSEcCtD
Pazopanib—Dizziness—Methotrexate—lung cancer	7.77e-06	0.000114	CcSEcCtD
Pazopanib—Vomiting—Methotrexate—lung cancer	7.47e-06	0.00011	CcSEcCtD
Pazopanib—Rash—Methotrexate—lung cancer	7.41e-06	0.000109	CcSEcCtD
Pazopanib—Dermatitis—Methotrexate—lung cancer	7.41e-06	0.000109	CcSEcCtD
Pazopanib—Headache—Methotrexate—lung cancer	7.36e-06	0.000108	CcSEcCtD
Pazopanib—Asthenia—Doxorubicin—lung cancer	7.3e-06	0.000107	CcSEcCtD
Pazopanib—Pruritus—Doxorubicin—lung cancer	7.2e-06	0.000106	CcSEcCtD
Pazopanib—Nausea—Methotrexate—lung cancer	6.98e-06	0.000103	CcSEcCtD
Pazopanib—Diarrhoea—Doxorubicin—lung cancer	6.96e-06	0.000102	CcSEcCtD
Pazopanib—Dizziness—Doxorubicin—lung cancer	6.73e-06	9.9e-05	CcSEcCtD
Pazopanib—Vomiting—Doxorubicin—lung cancer	6.47e-06	9.52e-05	CcSEcCtD
Pazopanib—Rash—Doxorubicin—lung cancer	6.42e-06	9.44e-05	CcSEcCtD
Pazopanib—Dermatitis—Doxorubicin—lung cancer	6.41e-06	9.43e-05	CcSEcCtD
Pazopanib—Headache—Doxorubicin—lung cancer	6.38e-06	9.38e-05	CcSEcCtD
Pazopanib—Nausea—Doxorubicin—lung cancer	6.05e-06	8.89e-05	CcSEcCtD
Pazopanib—CYP3A4—Metabolism—PPP2R1B—lung cancer	3.5e-07	4.94e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—HRAS—lung cancer	3.5e-07	4.94e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—JUN—lung cancer	3.49e-07	4.94e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HRAS—lung cancer	3.49e-07	4.93e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—EGFR—lung cancer	3.48e-07	4.92e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—PIK3CA—lung cancer	3.48e-07	4.92e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MMP9—lung cancer	3.47e-07	4.91e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—VEGFA—lung cancer	3.47e-07	4.9e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTEN—lung cancer	3.47e-07	4.9e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—VEGFA—lung cancer	3.46e-07	4.89e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CDKN1A—lung cancer	3.46e-07	4.89e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MAPK3—lung cancer	3.46e-07	4.89e-06	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—AKT1—lung cancer	3.45e-07	4.88e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PTEN—lung cancer	3.45e-07	4.88e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—STAT3—lung cancer	3.44e-07	4.86e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—NRAS—lung cancer	3.43e-07	4.84e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—IL6—lung cancer	3.43e-07	4.84e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—STAT3—lung cancer	3.43e-07	4.84e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ABCB1—lung cancer	3.43e-07	4.84e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MYC—lung cancer	3.43e-07	4.84e-06	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—AKT1—lung cancer	3.42e-07	4.84e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—NRAS—lung cancer	3.42e-07	4.83e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—IL6—lung cancer	3.42e-07	4.83e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—AKT1—lung cancer	3.42e-07	4.83e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTT1—lung cancer	3.41e-07	4.82e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—HRAS—lung cancer	3.41e-07	4.82e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—HRAS—lung cancer	3.41e-07	4.82e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MMP9—lung cancer	3.4e-07	4.8e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—lung cancer	3.4e-07	4.8e-06	CbGpPWpGaD
Pazopanib—FGFR2—Disease—AKT1—lung cancer	3.39e-07	4.79e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CDKN1A—lung cancer	3.39e-07	4.79e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—MAPK3—lung cancer	3.38e-07	4.78e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PTEN—lung cancer	3.38e-07	4.78e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GCLC—lung cancer	3.37e-07	4.77e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP2A6—lung cancer	3.37e-07	4.77e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—TYMS—lung cancer	3.36e-07	4.76e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MYC—lung cancer	3.36e-07	4.75e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—EGFR—lung cancer	3.35e-07	4.73e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—IL6—lung cancer	3.35e-07	4.73e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CYP1A1—lung cancer	3.35e-07	4.73e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL6—lung cancer	3.34e-07	4.71e-06	CbGpPWpGaD
Pazopanib—KIT—Disease—AKT1—lung cancer	3.33e-07	4.71e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GSTM1—lung cancer	3.33e-07	4.7e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ERCC2—lung cancer	3.32e-07	4.69e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—STK11—lung cancer	3.31e-07	4.68e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—EP300—lung cancer	3.31e-07	4.67e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MDM2—lung cancer	3.3e-07	4.66e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—APOA1—lung cancer	3.3e-07	4.66e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EP300—lung cancer	3.29e-07	4.65e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—EGFR—lung cancer	3.29e-07	4.65e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—KRAS—lung cancer	3.29e-07	4.65e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—MYC—lung cancer	3.29e-07	4.65e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—RAF1—lung cancer	3.28e-07	4.64e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MAPK3—lung cancer	3.28e-07	4.64e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MAPK3—lung cancer	3.27e-07	4.63e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL6—lung cancer	3.27e-07	4.62e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IL6—lung cancer	3.26e-07	4.61e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—HRAS—lung cancer	3.25e-07	4.59e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ERBB2—lung cancer	3.25e-07	4.59e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EP300—lung cancer	3.22e-07	4.56e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—HRAS—lung cancer	3.22e-07	4.55e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—EGFR—lung cancer	3.22e-07	4.54e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTEN—lung cancer	3.21e-07	4.54e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CB—lung cancer	3.21e-07	4.53e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MTOR—lung cancer	3.21e-07	4.53e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—SRC—lung cancer	3.2e-07	4.52e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ENO1—lung cancer	3.2e-07	4.52e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MYC—lung cancer	3.19e-07	4.51e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MYC—lung cancer	3.18e-07	4.5e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—KRAS—lung cancer	3.17e-07	4.47e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—AKT1—lung cancer	3.16e-07	4.47e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.16e-07	4.46e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—AKT1—lung cancer	3.15e-07	4.46e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CYP1A1—lung cancer	3.15e-07	4.46e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—SRC—lung cancer	3.13e-07	4.43e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ERCC2—lung cancer	3.13e-07	4.42e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—EGFR—lung cancer	3.12e-07	4.41e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—VEGFA—lung cancer	3.12e-07	4.41e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—EGFR—lung cancer	3.11e-07	4.4e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IL6—lung cancer	3.11e-07	4.4e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	3.11e-07	4.4e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—KRAS—lung cancer	3.11e-07	4.39e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—AKT1—lung cancer	3.09e-07	4.36e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—STAT3—lung cancer	3.09e-07	4.36e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CXCL8—lung cancer	3.08e-07	4.35e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NRAS—lung cancer	3.08e-07	4.35e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—IL6—lung cancer	3.08e-07	4.35e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—AKT1—lung cancer	3.08e-07	4.35e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSTP1—lung cancer	3.07e-07	4.33e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—EP300—lung cancer	3.06e-07	4.33e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—VEGFA—lung cancer	3.05e-07	4.31e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—KRAS—lung cancer	3.04e-07	4.29e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—PIK3CA—lung cancer	3.02e-07	4.27e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—STAT3—lung cancer	3.02e-07	4.27e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NRAS—lung cancer	3.02e-07	4.26e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—AKT1—lung cancer	3.01e-07	4.26e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—AKT1—lung cancer	3.01e-07	4.25e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CG—lung cancer	3.01e-07	4.25e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CAT—lung cancer	2.98e-07	4.22e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.97e-07	4.19e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—KRAS—lung cancer	2.95e-07	4.17e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MAPK3—lung cancer	2.95e-07	4.17e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CASP3—lung cancer	2.95e-07	4.17e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL2—lung cancer	2.94e-07	4.16e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—KRAS—lung cancer	2.94e-07	4.16e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PIK3CA—lung cancer	2.91e-07	4.11e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ABCB1—lung cancer	2.9e-07	4.1e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MAPK3—lung cancer	2.89e-07	4.08e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—APOA1—lung cancer	2.87e-07	4.06e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCND1—lung cancer	2.87e-07	4.06e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—AKT1—lung cancer	2.87e-07	4.06e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP2E1—lung cancer	2.87e-07	4.06e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MYC—lung cancer	2.87e-07	4.05e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—JUN—lung cancer	2.86e-07	4.05e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—POMC—lung cancer	2.86e-07	4.05e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PIK3CA—lung cancer	2.86e-07	4.04e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—TYMS—lung cancer	2.85e-07	4.03e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—AKT1—lung cancer	2.84e-07	4.02e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NQO1—lung cancer	2.84e-07	4.01e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSTM1—lung cancer	2.82e-07	3.98e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—lung cancer	2.81e-07	3.98e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MYC—lung cancer	2.81e-07	3.97e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EGFR—lung cancer	2.81e-07	3.97e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—HRAS—lung cancer	2.8e-07	3.95e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—PIK3CA—lung cancer	2.79e-07	3.94e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CREBBP—lung cancer	2.79e-07	3.94e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MMP9—lung cancer	2.79e-07	3.94e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CDKN1A—lung cancer	2.78e-07	3.92e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PTEN—lung cancer	2.77e-07	3.92e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—lung cancer	2.76e-07	3.9e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EGFR—lung cancer	2.75e-07	3.88e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PIK3CA—lung cancer	2.71e-07	3.83e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—APOA1—lung cancer	2.71e-07	3.82e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PIK3CA—lung cancer	2.7e-07	3.82e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—HRAS—lung cancer	2.69e-07	3.8e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL6—lung cancer	2.68e-07	3.78e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP1A1—lung cancer	2.67e-07	3.77e-06	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PIK3CA—lung cancer	2.67e-07	3.77e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—KRAS—lung cancer	2.65e-07	3.75e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ERCC2—lung cancer	2.65e-07	3.74e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CD—lung cancer	2.64e-07	3.74e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—HRAS—lung cancer	2.64e-07	3.73e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EP300—lung cancer	2.64e-07	3.73e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—lung cancer	2.62e-07	3.71e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CG—lung cancer	2.62e-07	3.7e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—lung cancer	2.62e-07	3.7e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ALB—lung cancer	2.61e-07	3.69e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KRAS—lung cancer	2.6e-07	3.67e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—HRAS—lung cancer	2.58e-07	3.65e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL6—lung cancer	2.57e-07	3.64e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—SRC—lung cancer	2.57e-07	3.63e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—STK11—lung cancer	2.56e-07	3.61e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL6—lung cancer	2.53e-07	3.57e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—HRAS—lung cancer	2.51e-07	3.54e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—VEGFA—lung cancer	2.5e-07	3.54e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—HRAS—lung cancer	2.5e-07	3.53e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—POMC—lung cancer	2.49e-07	3.53e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—STAT3—lung cancer	2.48e-07	3.5e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NRAS—lung cancer	2.47e-07	3.49e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—IL6—lung cancer	2.47e-07	3.49e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CG—lung cancer	2.47e-07	3.49e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—AKT1—lung cancer	2.47e-07	3.49e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PIK3CA—lung cancer	2.45e-07	3.46e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PIK3CA—lung cancer	2.44e-07	3.44e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CREBBP—lung cancer	2.43e-07	3.43e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL6—lung cancer	2.4e-07	3.39e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL6—lung cancer	2.39e-07	3.38e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PIK3CA—lung cancer	2.38e-07	3.37e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—AKT1—lung cancer	2.38e-07	3.36e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MAPK3—lung cancer	2.37e-07	3.35e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTP1—lung cancer	2.37e-07	3.34e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—lung cancer	2.36e-07	3.33e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—POMC—lung cancer	2.35e-07	3.32e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—AKT1—lung cancer	2.33e-07	3.3e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—lung cancer	2.31e-07	3.26e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CB—lung cancer	2.31e-07	3.26e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CD—lung cancer	2.3e-07	3.26e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CAT—lung cancer	2.3e-07	3.25e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MYC—lung cancer	2.3e-07	3.25e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—APOA1—lung cancer	2.29e-07	3.24e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CREBBP—lung cancer	2.29e-07	3.24e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTGS2—lung cancer	2.28e-07	3.23e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—AKT1—lung cancer	2.28e-07	3.22e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ALB—lung cancer	2.27e-07	3.21e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PIK3CA—lung cancer	2.26e-07	3.2e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—HRAS—lung cancer	2.25e-07	3.18e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EGFR—lung cancer	2.25e-07	3.18e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ABCB1—lung cancer	2.24e-07	3.17e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—AKT1—lung cancer	2.21e-07	3.13e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—AKT1—lung cancer	2.21e-07	3.12e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—HRAS—lung cancer	2.21e-07	3.12e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—TYMS—lung cancer	2.2e-07	3.11e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.19e-07	3.1e-06	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—AKT1—lung cancer	2.18e-07	3.08e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTM1—lung cancer	2.17e-07	3.07e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CD—lung cancer	2.17e-07	3.07e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL6—lung cancer	2.16e-07	3.05e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ALB—lung cancer	2.14e-07	3.03e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KRAS—lung cancer	2.13e-07	3.01e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL6—lung cancer	2.11e-07	2.98e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CG—lung cancer	2.09e-07	2.96e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP1A1—lung cancer	2.06e-07	2.91e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ERCC2—lung cancer	2.04e-07	2.89e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CB—lung cancer	2.01e-07	2.84e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—AKT1—lung cancer	2e-07	2.82e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTEN—lung cancer	1.99e-07	2.82e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—POMC—lung cancer	1.99e-07	2.81e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTGS2—lung cancer	1.99e-07	2.81e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—AKT1—lung cancer	1.99e-07	2.81e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CA—lung cancer	1.95e-07	2.76e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—AKT1—lung cancer	1.95e-07	2.75e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CREBBP—lung cancer	1.94e-07	2.74e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—EP300—lung cancer	1.9e-07	2.68e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CB—lung cancer	1.89e-07	2.67e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—lung cancer	1.89e-07	2.67e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTGS2—lung cancer	1.88e-07	2.65e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—AKT1—lung cancer	1.85e-07	2.61e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CD—lung cancer	1.84e-07	2.6e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ALB—lung cancer	1.82e-07	2.57e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—HRAS—lung cancer	1.81e-07	2.56e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—APOA1—lung cancer	1.77e-07	2.5e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTEN—lung cancer	1.74e-07	2.45e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL6—lung cancer	1.73e-07	2.45e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—EP300—lung cancer	1.65e-07	2.34e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTEN—lung cancer	1.64e-07	2.31e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CG—lung cancer	1.61e-07	2.28e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CB—lung cancer	1.6e-07	2.27e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—AKT1—lung cancer	1.6e-07	2.26e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTGS2—lung cancer	1.59e-07	2.24e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—EP300—lung cancer	1.56e-07	2.2e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—POMC—lung cancer	1.54e-07	2.17e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CREBBP—lung cancer	1.5e-07	2.12e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CD—lung cancer	1.42e-07	2.01e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CA—lung cancer	1.41e-07	1.99e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ALB—lung cancer	1.4e-07	1.98e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTEN—lung cancer	1.39e-07	1.96e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—EP300—lung cancer	1.32e-07	1.87e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CB—lung cancer	1.24e-07	1.75e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTGS2—lung cancer	1.23e-07	1.73e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CA—lung cancer	1.22e-07	1.73e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CA—lung cancer	1.15e-07	1.63e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—AKT1—lung cancer	1.15e-07	1.62e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTEN—lung cancer	1.07e-07	1.51e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—EP300—lung cancer	1.02e-07	1.44e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—AKT1—lung cancer	1e-07	1.41e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CA—lung cancer	9.77e-08	1.38e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—AKT1—lung cancer	9.42e-08	1.33e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AKT1—lung cancer	7.98e-08	1.13e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CA—lung cancer	7.54e-08	1.07e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AKT1—lung cancer	6.16e-08	8.71e-07	CbGpPWpGaD
